Overview
UK natural extracts maker's H1 revenue fell 6.5% on lower Heritage and Premium volumes
Adjusted pretax profit and adjusted EPS declined year-on-year amid challenging market conditions
Company did not declare interim dividend following recommended takeover offer from Döhler
Outlook
Treatt expects full-year performance in line with management expectations
Company sees greater weighting of FY26 results to H2 than in FY25
Treatt anticipates returning to net cash by year end
Result Drivers
CITRUS MARKET WEAKNESS - Co said lower citrus sales and slow recovery in the citrus market weighed on revenue and profit
PREMIUM VOLUME DECLINE - Lower volumes in Premium products contributed to revenue and profit declines
HEALTH & WELLNESS GROWTH - Strong year-on-year growth in health & wellness, particularly in sugar reduction and low-and-no beverage applications, partly offset declines elsewhere
Company press release: ID:nRSc2931Ca
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
GBP 59.9 mln
H1 Gross Margin
24.9%
H1 Adjusted Pretax Profit
GBP 2.5 mln
H1 Gross Profit
GBP 14.92 mln
H1 Pretax Profit
GBP 2 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the food processing peer group is "buy"
Wall Street's median 12-month price target for Treatt PLC is GBp231.00, about 12.4% above its April 28 closing price of GBp205.50
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)